.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,911,778

« Back to Dashboard

Claims for Patent: 8,911,778

Title:Pellet formulation for the treatment of the intestinal tract
Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE), Gruber; Peter (Merzhausen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:13/566,905
Patent Claims: 1. A controlled release pellet formulation comprising: homogeneously dispersed 5-aminosalicyclic acid in a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid; and an enteric coating; wherein, when administered to humans, the average cumulative fecal excretion of 5-aminosalicyclic acid is greater than 250 mg.

2. The controlled release pellet formulation of claim 1, wherein the average cumulative fecal excretion is measured approximately 72 hours after administration.

3. The controlled release pellet formulation of claim 2, wherein the average cumulative fecal excretion of 5-aminosalicyclic acid is greater than 280 mg.

4. The controlled release pellet formulation of claim 2, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is greater than 330 mg.

5. The controlled release pellet formulation of claim 4, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is greater than 360 mg.

6. The controlled release formulation of claim 1, wherein the polymer matrix comprises at least 1% by weight of the total weight of the core.

7. The controlled release formulation of claim 6, wherein the polymer matrix comprises poly(ethyl acrylate, methyl methacrylate) or poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

8. The controlled release formulation of claim 1, wherein the controlled release formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps, or colorectal cancer.

9. The controlled release formulation of claim 8, wherein the inflammatory intestinal disorder comprise Crohn's disease or ulcerative colitis.

10. The controlled release formulation of claim 1, wherein the controlled release formulation is used for the maintenance of remission of ulcerative colitis.

11. A controlled release pellet formulation comprising: homogeneously dispersed 5-aminosalicyclic acid in a polymer matrix, wherein the polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid; and an enteric coating; wherein, when administered to humans, the average cumulative fecal excretion of 5-aminosalicyclic acid is about 25% higher than 5-aminosalicyclic acid in the form of enteric tablets.

12. The controlled release formulation of claim 11, the average cumulative fecal excretion of 5-aminosalicyclic acid is about 29% higher than 5-aminosalicyclic acid in the form of enteric tablets.

13. The controlled release formulation of claim 12, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is about 40% higher than acetyl-5-aminosalicyclic acid produced from 5-aminosalicyclic acid in the form of enteric tablets.

14. The controlled release formulation of claim 13, wherein the average cumulative fecal excretion of acetyl-5-aminosalicyclic acid is about 44% higher than acetyl-5-aminosalicyclic acid produced from 5-aminosalicyclic acid in the form of enteric tablets.

15. The controlled release formulation of claim 11, wherein the polymer matrix comprises at least 1% by weight of the total weight of the core.

16. The controlled release formulation of claim 15, wherein the polymer matrix comprises poly(ethyl acrylate, methyl methacrylate) or poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

17. The controlled release formulation of claim 11, wherein the controlled release formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps, or colorectal cancer.

18. The controlled release formulation of claim 17, wherein the inflammatory intestinal disorder comprise Crohn's disease or ulcerative colitis.

19. The controlled release formulation of claim 11, wherein the controlled release formulation is used for the maintenance of remission of ulcerative colitis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc